Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia Could See Double COX-2 NME Drug Approvals In 2001

Executive Summary

Pharmacia could gain approval of two COX-2 inhibitor drugs that are new molecular entities by late 2001.
Advertisement

Related Content

FDA Drug Approval Time Edges Up To 18.5 Months In 2001
FDA Drug Approval Time Edges Up To 18.5 Months In 2001
Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps
FDA Approval Decisions Changing In Light Of Relabeling Failures - Woodcock
Novartis Atopic Dermatitis Drug Elidel Launch Projected For 2002
FDA Lotronex Letter Cites Desire To Work With Glaxo To Maintain Therapy
Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8
Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8
Schering-Plough desloratadine
Wall Street Cool On Claritin Defense: Schering Prepares For Desloratadine
Advertisement
UsernamePublicRestriction

Register

PS037149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel